Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
treatment symbols : Mbrx save search
European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 4.91%
H: 11.36%
C: 0.67%
drug treatment designation for grants leukemia
Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases
Published: 2023-11-06 (Crawled : 13:30) - prnewswire.com
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 0.67%
H: 16.45%
C: 14.21%
lung disease positive treatment trial
Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Published: 2023-10-02 (Crawled : 13:00) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 2.46%
H: 0.0%
C: -0.23%
treatment leukemia trial
Moleculin Announces Completion of Enrollment in U.S. Phase 1B/2 Clinical Trial Evaluating Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases (MB107)
Published: 2023-09-21 (Crawled : 13:30) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: -0.03%
H: 9.98%
C: 9.98%
mb107 lung treatment trial
Moleculin Announces Publication of Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
Published: 2023-07-13 (Crawled : 14:00) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 6.47%
H: 27.69%
C: 10.57%
publication treatment leukemia trial
Moleculin Successfully Completes First Cohort in Phase 1b/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Published: 2023-05-02 (Crawled : 13:20) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: -0.65%
H: 7.89%
C: 5.26%
treatment leukemia trial
Moleculin Announces Publication of Data Supporting Development of Non-Cardiotoxic Anthracycline for the Treatment of Cancer in Peer-Reviewed European Journal of Cancer
Published: 2023-03-09 (Crawled : 18:00) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 0.82%
H: 2.06%
C: -5.69%
treatment cancer publication
Moleculin Announces Dosing of First Subject in Italy for Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Published: 2023-03-01 (Crawled : 14:00) - prnewswire.com
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: -0.1%
H: 3.41%
C: -0.73%
treatment leukemia trial
Moleculin Announces Final Topline Data from Successful European Phase 1 Trial Evaluating Annamycin as Single Agent Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)
Published: 2023-02-13 (Crawled : 13:20) - prnewswire.com
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 5.82%
H: 4.84%
C: -4.84%
treatment topline leukemia trial phase 1
Moleculin Receives Approval in Italy to Conduct Phase 1/2 Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML)
Published: 2022-12-21 (Crawled : 14:00) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: -1.52%
H: 0.18%
C: -3.85%
treatment leukemia trial approval acute myeloid leukemia aml phase 1
Moleculin Reports 80% Overall Response Rate in Final Cohort of Phase 1 Single Agent Trial of Annamycin for the Treatment of Acute Myeloid Leukemia (AML)
Published: 2022-12-15 (Crawled : 20:00) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 6.67%
H: 4.17%
C: -4.17%
treatment leukemia trial response acute myeloid leukemia aml
Moleculin Granted FDA Fast Track Designation of WP1122 for the Treatment of Glioblastoma Multiforme
Published: 2022-12-07 (Crawled : 14:00) - prnewswire.com
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 3.88%
H: 12.69%
C: 11.19%
wp1122 treatment fda designation granted fast track designation glioblastoma
Moleculin Receives FDA Orphan Drug Designation of WP1122 for the Treatment of Glioblastoma Multiforme
Published: 2022-09-06 (Crawled : 13:00) - prnewswire.com
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 0.0%
H: 1.66%
C: -3.5%
wp1122 treatment fda designation drug glioblastoma
Moleculin Concludes Phase 1b and Opens Recruitment in Phase 2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
Published: 2022-07-28 (Crawled : 13:00) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: -2.96%
H: 4.27%
C: 3.66%
treatment trial phase 2 soft tissue phase 2b
Moleculin Commences Dosing in Healthy Volunteers in Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
Published: 2022-05-26 (Crawled : 13:20) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 2.22%
H: 5.8%
C: 4.35%
wp1122 covid-19 treatment trial phase 1
Moleculin Receives Approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for Protocol Amendment to Phase 1a Clinical Trial of WP1122 for the Treatment of COVID-19
Published: 2022-05-10 (Crawled : 13:00) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 2.64%
H: 4.39%
C: -2.94%
wp1122 covid-19 treatment trial approval phase 1
Moleculin Receives Allowance to Proceed with Phase 1/2 Study of Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia (AML)
Published: 2022-05-05 (Crawled : 13:00) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: -0.64%
H: 0.65%
C: -3.87%
treatment leukemia phase 1 acute myeloid leukemia aml
Moleculin Receives IND Clearance to Conduct Phase 1 Study of WP1066 for the Treatment of Recurrent Malignant Glioma
Published: 2022-04-21 (Crawled : 13:20) - prnewswire.com
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: 0.0%
wp1066 treatment clearance phase 1
Moleculin Announces Preliminary Third Cohort Interim Data in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Soft Tissue Sarcoma Lung Metastases
Published: 2021-12-27 (Crawled : 13:30) - biospace.com/
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 0.99%
H: 0.0%
C: -9.76%
treatment phase 1b trial phase 1 soft tissue phase 2b
Moleculin Receives FDA Allowance to Begin a Phase 1 Study of WP1122 for the Treatment of Glioblastoma Multiforme
Published: 2021-12-01 (Crawled : 13:30) - prnewswire.com
MBRX | $4.65 2.8% 2.72% 11K
|
Health Technology
|
| O: 1.22%
H: 10.14%
C: 5.8%
treatment fda phase 1 phase 2 glioblastoma
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.